Liver disease Archives

Latest Posts

News and Trends 19 Sep 2022

GENFIT to acquire Versantis to expand liver disease portfolio

GENFIT has entered into an exclusivity agreement with a view to acquire all the share capital and voting rights of Versantis, a private Swiss-based clinical stage biotechnology company focused on…

September 19, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 28 Jun 2022

Companies unite to bolster diagnostics for cancer and liver disease

Two companies set on making improvements for those with lung cancer, non-alcoholic fatty liver disease and breast cancer have partnered in a bid to bolster noninvasive diagnostics for the conditions.…

June 28, 2022 - 2 minutesmins - By Liza Laws

News and Trends 28 Jun 2022

Eiger BioPharmaceuticals presents liver study data

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharma company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, has announced data presented…

June 28, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 19 Jan 2022

Engitix Builds Liver Disease Pipeline with Series A and Drug Collaboration

With the close of its Series A round at €48M ($54M), the tissue models company Engitix has shifted its business from providing drug discovery services to developing its own treatment…

January 19, 2022 - 3 minutesmins - By Jonathan Smith

Infographics by

26 Jan 2021

Infographic: The Key Role of Imaging in Clinical Trials

Medical imaging techniques, such as magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound have emerged as promising biomarkers in clinical trials. This brand new infographic, created in collaboration with…

January 26, 2021 - 2 minutesmins - By Maya Chergova

News and Trends 21 Jan 2020

German Biotech Raises €11M to Regenerate Liver Damage

Biotech company HepaRegeniX has raised a Series B round that will allow its first candidate drug for liver disease to enter clinical trials later this year. Based in…

January 21, 2020 - 2 minutesmins - By Clara Rodríguez Fernández

HEADER destroyed liver Transcure Kateryna Kon

Treating Liver Diseases: Is This Preclinical Model the Solution?

Liver diseases are on the rise. Although many drug candidates are being developed, preclinical toxicity, drug metabolism and drug-drug interaction studies remain challenging without a predictive model. One company is…

December 4, 2019 - 6 minutesmins - By Larissa Warneck-Silvestrin

Can This Cell Therapy Help Fight the NASH Epidemic?

Nonalcoholic steatohepatitis (NASH) is the most severe form of nonalcoholic fatty liver disease (NAFLD) and is characterized by a fatty liver, inflammation, and liver cell damage. If left untreated, NASH…

November 4, 2019 - 7 minutesmins - By Larissa Warneck-Silvestrin

More News! 18 Sep 2019

€15M to Take Swiss Biotech’s Liver Cirrhosis Treatment to Phase II

Versantis has raised a Series B of €14.6M (CHF 16M) to advance its treatment for late-stage liver cirrhosis to a phase IIa trial. The money will finance the completion of…

September 18, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 17 Dec 2019

Update: Cell Therapy Biotech Raises €47M to Fund NASH Clinical Trial

Update (17/12/2019): Promethera has increased the total raised in its Series D round to €47.2M with the addition of new investors, including Innovation Growth Ventures and Pegasus Tech Ventures among…

December 17, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 2 May 2019

Drug for Autoimmune Liver Disease Yields Mixed Results in Hard-to-Treat Patients

Developed by the French biotech Genkyotex, a first-in-class treatment for the liver disease primary biliary cholangitis failed to reduce a key disease biomarker in a phase II trial, but showed…

May 2, 2019 - 2 minutesmins - By Jonathan Smith

liver fibrosis alentis switzerland cirrhosis cancer

News and Trends 30 Apr 2019

Swiss Biotech Raises €11M to Develop Treatments for Liver Fibrosis

Founded in March this year, Alentis Therapeutics has bagged a Series A round of €11.1M (CHF 12.5M) to develop antibody drugs treating liver fibrosis, which currently has no approved treatments.…

April 30, 2019 - 2 minutesmins - By Jonathan Smith

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

Download Inpart’s latest report

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering